retatrutide for menopause Promises Big Weight Loss, but Safety Remains a Question Retatrutide Dosing: Early Clinical Trial
Description
One study found that exenatide, a GLP-1 agonist that was approved to treat Type 2 diabetes back in 2005, significantly reduced the alcohol-cue reactivity in the area of the brain related to drug reward and addiction and significantly reduced the total alcohol intake in patients with obesity in particular
These data highlight important geographic disparities in research intensity and access to clinical trials worldwide
After eating, GLP-1 levels rise, signaling the brain that the body has consumed enough food
Briand, B
doi: 10.1210/en.2002-220405 [DOI] [PubMed] [Google Scholar] 126
